Our Research and Development team comprises of experienced and well qualified Doctors, scientists, and chemists who have been working continuously for the discovery and development of the new products and improving the existing ones.
Along with this our scientific team gets continuous updates from the market research team to understand the market need and with the help of Medical statistics team new product requirement is finalized. In this way we tend to reach the patient in a shorter span of time with low cost products.
We have been working on various areas of research out of which following are the main thrust areas.
Beauty Products – We develop natural solutions for skin, hair and other beauty related products. Our Mantra Herbal range based on the ageless principles of Ayurveda is a step in this direction. We are continuously striving for chemical free personal care products and were able to remove major harmful chemicals like Parabens, Paraffin, Phthalates, Silicones, SLES, SLS, Soap, Synthetic dyes, synthetic fragrances, formaldehyde donors, and Ethanolamine from our products.
Clinical Research & Trials – We deliver best quality products with greater efficacy and minimal adverse events. Our dedicated team of Clinical Researchers, Doctors, chemists, and others is working whole heartedly on New Formulations and improving existing ones by conducting series of Clinical Trials at multiple centers.
We are one of the largest collaborators in industry and work with academic institutions, governments, and other pharmaceutical and biotechnology companies. We believe that the strength of our combined efforts will ultimately help people do more, feel better, and live longer. To develop and authenticate the efficacy of these products, Ayurvedant along with Badiyanath Research Foundation have long collaborated with various premier knowledge centers like Banaras Hindu University, Gujarat Ayurveda University Jamnagar, SASTRA University Thanjavur and Bundelkhand University Jhansi.
Ayurvedant is the first company to have US patent for an Ayurvedic medicine CARDIWIN which is jointly developed by Banaras Hindu University and BRF. US Patent department has acknowledged this Ayurvedic formulation for prevention and management of Coronary Heart Disease.
Like all innovative pharmaceutical companies, we carry out a series of clinical trials to test each investigational drug for the potential to become a new medicine.
The effect of the potential drug will often be compared to that of an inactive substance, a placebo, which is prepared to look like the drug so as to prevent bias during the trial. The investigational drug may also be compared against marketed medicines.
Phase I trials typically involve healthy volunteers. These trials study the safety of the drug and its interaction with the body, for example, its concentration and duration in the blood following various doses, and begin to answer such questions as whether the drug inhibits or amplifies the effects of other medicines that might be taken at the same time.
Phase II studies enroll patients with the illness an investigational drug is designed to treat. These trials evaluate whether the drug shows favorable effects in treating an illness and seek to determine the proper dose. They provide an opportunity to explore the therapeutic potential of the drug in what may be quite different illnesses. The evaluation of safety continues.
If Phase II results have been encouraging, Phase III trials, the largest part of a clinical-development program, go forward. Phase III trials are designed to provide the substantial evidence of efficacy and safety required, in addition to data from earlier-phase trials, before regulatory agencies will approve the investigational drug as a medicine and allow it to be marketed.
Trials of a medicine may continue even after it has been approved for marketing. Known as Phase IV trials, they may further evaluate the effect of the medicine for the approved use, assess other potential uses, or yield additional safety data. Regulatory agencies may require these trials to address specific questions.
Given the exploratory nature of clinical development, investigators often need to conduct trials of varying designs to determine the potential of an investigational drug and its best use. Rarely does anyone’s trial enable a full understanding.
Therefore, a pharmaceutical company performs a comprehensive analysis of its studies for submission to regulatory agencies. The prescribing information ultimately approved by those agencies, following their own authoritative, cross-study analyses, directs the appropriate use of the medicine.
Although pharmaceutical companies design and take responsibility for the trials they sponsor, any clinical-development program ultimately depends on the commitment of physician-investigators and the patients they enroll in the settings of clinics and hospitals. A new medicine, or new use of a medicine, is the result of a collaborative, often international effort.